Early-stage asset forecasts featuring FlexiCastTM

Providing evidence-based early-stage asset forecasting models to the pharmaceutical industry

Early stage asset forecasting focuses on the variables that lead to greatest forecast uncertainty

Bespoke forecast models are built to your specific pharmaceutical forecast requirements. To maximize the power and stability of your pharma forecast, Inpharmation use FlexiCast as the starting point for all your demand forecasting needs.

FlexiCast is an evidence-based pharma forecasting toolbox; developed by experts, specifically for the challenges faced by pharmaceutical forecasting, business development and marketing teams when building bespoke forecasts:

  • A modular approach reduces forecast errors; most new forecasts contain errors. In fact studies show that 94% of spreadsheet models contain serious errors when not built using our modular forecasting software, FlexiCast.
  • An evidence-based approach achieves a 30% reduction in error for Inpharmation’s final share forecasts vs. non-Pharma-Specific™ approaches.*
  • Most forecasting models for the pharmaceutical industry incorrectly simulate therapy area-specific dynamics, such as multiple treatment steps in oncology forecasts. Inpharmation has two decades of experience delivering Pharma-Specific bespoke forecast models.
*Taking a combined forecast approach using Pharma-Specific approach vs. a standard approach.
**Errors found in audit of 88 non-modular spreadsheet models.
Errors found in audit of 88 non-modular spreadsheet models.**

Inpharmation specializes in finding the best validated approaches to answering your strategic business questions, with decades of experience answering the following types of questions:
  • I need to understand which asset to purchase… How can I quantify the pharma-relevant risks and translate these into a strategic recommendation?
  • I have limited access to forecast data… What is the best strategic approach to designing my therapy area (e.g. oncology) forecast?
  • I have a large number of market segments to forecast… How can I quickly forecast which are relevant?
  • I have to generate a brand forecast for 80 countries… How can I roll-out and consolidate all the forecasts, assumptions and results?
  • I have a flow model/Markov model which produces illogical results… How can I calibrate my forecast using an evidence-based approach?
Years of experience delivering Pharma-Specific bespoke forecast models.

“The FlexiCast tool can help with many aspects of the sales forecasting process, even as an add on to existing tools you are already using.”

Top 10 Pharma Company

“… the largest advantage to this tool is the ability to easily update the assumptions…”

“Owing to the successful implementation of FlexiCast… and the acceptance of the methodology by Sr. Management, a decision has been made to expand usage…”

Top 10 Pharma Company

“Europe’s most respected pharma forecasting specialist consultancy.”

Centre For Executive Leadership for Pharma

Evidence-based forecasting models for the pharmaceutical industry

40% of the top-50 global pharma companies use Inpharmation’s evidence-based forecasting platform. When you need accurate and reliable forecasts, you need solutions that are based upon validated, Pharma-Specific models and tools.

Most importantly, bespoke forecasting models for the pharmaceutical industry are specific to your strategic business questions:

  • With 73 different forecast models, FlexiCast has evidence-based forecast models that are appropriate for all main therapy areas. What’s more, these have been validated for pharmaceutical forecasting.
  • DataTreeTM meets your requirements for forecasting multiple therapy areas and countries in a single forecast interface.
  • Our decades of experience answering bespoke pharmaceutical forecast questions means we have developed customized risk models and flow models to meet your strategic forecast questions.

Included in all FlexiCast software licenses is industry-leading software training. 93% of course attendees highly rate our forecasting training.

The evidence behind Inpharmation’s fact-based approach to pricing is meticulously documented in the book Sales Forecasting for Pharmaceuticals: An Evidence-Based Approach by Inpharmation’s founder and Chairman, Gary Johnson.

Request a free evidence-based Sales Forecasting for Pharmaceuticals information pack

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top